Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.

Date publication

juillet 2014

Journal

Inflammatory bowel diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24831559

Résumé

The aim of this meta-analysis was to explore the magnitude of the association between pharmacokinetics of adalimumab and clinical response in patients with inflammatory bowel disease.

Mots clés

Adalimumab, Adult, Age Factors, Antibodies, Monoclonal, Humanized, pharmacokinetics, Child, Colitis, Ulcerative, diagnosis, Crohn Disease, diagnosis, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Inflammatory Bowel Diseases, diagnosis, Male, Monitoring, Physiologic, Risk Assessment, Severity of Illness Index, Treatment Outcome

Référence

Inflamm. Bowel Dis.. 2014 Jul;20(7):1288-95